Last reviewed · How we verify
Atu027 & gemcitabine in treatment arm 1 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Atu027 & gemcitabine in treatment arm 1 (Atu027 & gemcitabine in treatment arm 1) — Silence Therapeutics GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Atu027 & gemcitabine in treatment arm 1 TARGET | Atu027 & gemcitabine in treatment arm 1 | Silence Therapeutics GmbH | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Atu027 & gemcitabine in treatment arm 1 CI watch — RSS
- Atu027 & gemcitabine in treatment arm 1 CI watch — Atom
- Atu027 & gemcitabine in treatment arm 1 CI watch — JSON
- Atu027 & gemcitabine in treatment arm 1 alone — RSS
Cite this brief
Drug Landscape (2026). Atu027 & gemcitabine in treatment arm 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/atu027-gemcitabine-in-treatment-arm-1. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab